UBS Group Upgrades Davita (DVA) to “Neutral”
Davita (NYSE:DVA) was upgraded by equities researchers at UBS Group from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, 247wallst.com reports. The brokerage currently has a $59.00 target price on the stock, down from their prior target price of $64.00. UBS Group’s price objective points to a potential upside of 8.26% from the company’s current price.
Other equities analysts have also recently issued reports about the company. Zacks Investment Research cut Davita from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. ValuEngine cut Davita from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. Raymond James raised Davita from a “market perform” rating to an “outperform” rating and set a $70.00 target price for the company in a research report on Wednesday, November 28th. They noted that the move was a valuation call. Barclays assumed coverage on Davita in a research report on Friday, December 14th. They issued an “overweight” rating and a $70.00 target price for the company. Finally, JPMorgan Chase & Co. raised Davita from an “underweight” rating to a “neutral” rating in a research report on Thursday, September 13th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. Davita presently has a consensus rating of “Hold” and a consensus target price of $74.16.
Shares of NYSE DVA traded up $0.58 during mid-day trading on Tuesday, reaching $54.50. The company had a trading volume of 11,381 shares, compared to its average volume of 1,604,607. The company has a quick ratio of 1.82, a current ratio of 1.84 and a debt-to-equity ratio of 2.09. The stock has a market capitalization of $8.96 billion, a price-to-earnings ratio of 16.42, a PEG ratio of 0.53 and a beta of 1.25. Davita has a 1-year low of $48.25 and a 1-year high of $80.71.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Honkamp Krueger Financial Services Inc. acquired a new stake in shares of Davita in the third quarter worth about $143,000. Atlas Capital Advisors LLC lifted its position in shares of Davita by 247.9% in the third quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock worth $188,000 after buying an additional 1,847 shares during the last quarter. Green Square Capital LLC acquired a new stake in shares of Davita in the second quarter worth about $208,000. Captrust Financial Advisors lifted its position in shares of Davita by 96.8% in the third quarter. Captrust Financial Advisors now owns 3,050 shares of the company’s stock worth $218,000 after buying an additional 1,500 shares during the last quarter. Finally, Seven Eight Capital LP acquired a new stake in shares of Davita in the third quarter worth about $219,000. 85.66% of the stock is owned by hedge funds and other institutional investors.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.